Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation ...

Peter Ronco, CEO, Emmes, explains how the company is investing in transparent goal setting, comprehensive education, and ...

Cashin, MD, chief medical officer, Novotech, shares why clear communication, strong leadership, and cultural alignment are essential to building effective partnerships between CROs, sponsors, and ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous ...

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing ...

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

Cross-sector partnership launches EQBMED. Initially funded by PhRMA and established as a cross-sector collaborative, ...

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer ...

Cashin, MD, chief operating officer, Novotech, explains why seamless collaboration between CROs and sponsors is critical to advancing clinical trials, and reflects on Novotech’s recognition as ...